Savara Inc. (SVRA) CEO Rob Neville on Q1 2020 Results - Earnings Call Transcript

May 07, 2020 6:52 PM ETSavara Inc. (SVRA) StockSVRA
SA Transcripts
153.96K Followers

Q1: 2020-05-07 Earnings Summary

EPS of -$0.27 beats by $0.01
 | Revenue of $0.00 beats by $0.00

Savara Inc. (NASDAQ:SVRA) Q1 2020 Earnings Conference Call May 7, 2020 4:30 PM ET

Company Participants

Anne Erickson - VP, IR and Corporate Communications
Rob Neville - CEO
Badrul Chowdhury - Chief Medical Officer
Dave Lowrance - CFO
Taneli Jouhikainen - COO

Conference Call Participants

Edward Marks - Ladenburg Thalmann
Suji Jeong - Jefferies
Liisa Bayko - JMP Securities

Operator

Good day and welcome to the Savara conference call. At this time, all participants are in a listen-only mode. An audio webcast of this call will be available on the Investors section of Savara's Web site, at savarapharma.com. This call is subject to copyright and is the property of Savara. All recordings, reproduction, and transmission of this call without the expressed written consent of Savara is strictly prohibited. As a reminder, today's call is being recorded.

I would now like to turn the call over to Anne Erickson, Head Investor Relations and Corporate Communications at Savara. Please go ahead, ma'am.

Anne Erickson

Good afternoon and thank you for joining us today. A press release reporting our first quarter 2020 financial results was issued earlier today, May 7, 2020, and can be found on the Investors section of our Web site, at savarapharma.com. If you've not received this release or you would like to be added to the company's distribution list, please e-mail me at ir@savarapharma.com.

This call is also being webcast live, and one hour after the call a replay will be available on the company's Web site, and will remain available for the next 30 days. A telephone replay will be available through May 14. Today's conference call and webcast contain forward-looking statements within the meaning of federal securities laws, including statements regarding the company's strategy, goals, product candidates, clinical studies, and financing matters. Such statements are subject to significant risks and uncertainties, including those described in our press release

Recommended For You

About SVRA Stock

SymbolLast Price% Chg
Market Cap
PE
Yield
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

More on SVRA